There's no justification for these price hike", the drug pricing issue will remain in focus (Read more: Did Hillary Clinton's Tweet Cause the Sell-Off in Mylan Stock?). Novartis Scores Another Win in Biosimilar Segment: Novartis scored …
Mylan CEO Heather Bresch listens to an aide during a hearing before lying to the House Oversight and Government Reform Committee on September 21, 2016 (Photo by Alex Wong/Getty Images) Mylan, the drug company that makes EpiPen, …
Pharma giant Mylan has agreed to pay the federal government $465 million to settle questions of how the company’s EpiPen was classified under the Medicaid Drug Rebate Program. Mylan announced the deal late on Friday afternoon. …
Mylan N.V. MYL is scheduled to report second-quarter 2016 results on Aug 9, after market close. Mylan’s performance has been impressive with the company beating earnings estimates in three of the last four quarters. Overall, the …
Netherlands-based Mylan said it also intends to continue to market and distribute branded EpiPen. Mylan's shares were up about 1 percent at $43.53 in premarket trading. The stock had fallen 12 percent last week.
said last week that offering discounts without cutting the overall price was insufficient. Mylan shares rose 1% to $43.46 at 12:37 p.m. in New York. The stock had declined 12% last week as criticism mounted.